GlassScriptPhysician profile
Ifat Krase
NPI 1497021281
$1,370.21
in general payments reported to CMS, 2019-2025
18 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.84 · 2022: $388 · 2023: $232 · 2024: $313 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.37 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $241.97 | 2022-2023 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $191.53 | 2022-2025 | |
| Genzyme Corporation | $128.68 | 2024-2025 | |
| Csl Behring | $109.75 | 2023-2025 | Haegarda, Hizentra |
| Horizon Therapeutics Plc | $108.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.38 | 2023-2025 | Cuvitru, Hyqvia |
| Kaleo, INC. | $91.56 | 2023-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $90.02 | 2021-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $55.30 | 2025 | Neffy |
| Incyte Corporation | $46.14 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $26.01 | 2025 | Nemluvio |
| Greer Laboratories, INC. | $23.26 | 2025 | Palforzia |
| Biocryst US Sales Co., LLC | $20.43 | 2024 | Orladeyo |
| Phadia US INC. | $18.41 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $16.48 | 2025 | Alyglo |
| Alk-Abello, INC | $13.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ifat Krase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.